EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides an update on current trading.
The Company is pleased to announce that the trading in the second quarter of the year has continued the favourable trends experienced in the first quarter.
In particular, June sales were notably strong. This is entirely due to organic growth with no major tenders won during the period.
As a consequence, the Company expects adjusted EBITDA for 2017 will be comfortably ahead of current market forecasts.
Finally, despite the cancellation of the stock option scheme at a cost of £1.5m cash generation has been very strong with net cash at 30 June of approximately £4.0m.
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, Finance Director and COO
Tel: 00 44 29 2071 0570
|N+1 Singer (Nomad & Broker)
Alex Price / Alex Laughton-Scott
|Tel: 020 7496 3000
Walbrook PR Limited
|Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303